StockData
AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Aktis Oncology, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$15.11+0.05 (+0.33%)

Close on Oct 19, 2026

Market cap
$835.58M
P/E (TTM)
–
Dividend yield
–

Aktis Oncology, Inc. revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Aktis Oncology does not break out revenue by segment, region or product in the tagged data of its filings for this period type.